Arcus Biosciences, Inc.RCUS決算レポート
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
RCUS Q4 2025 Key Financial Metrics
売上高
$11.0M
粗利益
N/A
営業利益
$-114.0M
純利益
$-106.0M
粗利益率
N/A
営業利益率
-1036.4%
純利益率
-963.6%
前年比成長
-52.2%
EPS
$-0.88
資金フロー
Arcus Biosciences, Inc. Q4 2025 財務サマリー
Arcus Biosciences, Inc. reported revenue of $11.0M (down 52.2% YoY) for Q4 2025, with a net profit of $-106.0M (down 12.8% YoY) (-963.6% margin). Cost of goods sold was N/A.
主要財務指標
| 総売上高 | $11.0M |
|---|---|
| 純利益 | $-106.0M |
| 粗利益率 | N/A |
| 営業利益率 | -1036.4% |
| 報告期間 | Q4 2025 |
売上内訳
Arcus Biosciences, Inc. Q4 2025 revenue of $11.0M breaks down across 3 segments, led by Other at $5.0M (45.5% of total).
| セグメント | 売上高 | 構成比 |
|---|---|---|
| Other | $5.0M | 45.5% |
| Other Collaboration Revenue | $4.0M | 36.4% |
| Access Rights And Option Continuation Periods | $2.0M | 18.2% |
Arcus Biosciences, Inc. セグメント別売上 — 四半期推移
Arcus Biosciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Other Collaboration Revenue) has evolved quarter over quarter.
| セグメント | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Other | $5.0M | — | — | — |
| Other Collaboration Revenue | $4.0M | $6.0M | $8.0M | $8.0M |
| Access Rights And Option Continuation Periods | $2.0M | — | — | — |
Arcus Biosciences, Inc. 年度売上推移
Arcus Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.0M). Click any linked year to see what changed vs the prior 10-K.
Arcus Biosciences, Inc. 四半期売上・純利益の履歴
Arcus Biosciences, Inc. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $11.0M | -52.2% | $-106.0M | -963.6% |
| Q3 2025 | $6.0M | -14.3% | $-135.0M | -2250.0% |
| Q2 2025 | $8.0M | -27.3% | $0 | N/A |
| Q1 2025 | $8.0M | -20.0% | $-112.0M | -1400.0% |
| Q4 2024 | $23.0M | +146.9% | $-94.0M | -408.7% |
| Q3 2024 | $7.0M | -78.1% | $-92.0M | -1314.3% |
| Q2 2024 | $11.0M | -62.1% | $-93.0M | -845.5% |
| Q1 2024 | $10.0M | -60.0% | $-4.0M | -40.0% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $10.0M | $11.0M | $7.0M | $23.0M | $8.0M | $8.0M | $6.0M | $11.0M |
| 前年比成長 | -60.0% | -62.1% | -78.1% | 146.9% | -20.0% | -27.3% | -14.3% | -52.2% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $1.29B | $1.19B | $1.25B | $1.15B | $1.16B | $1.07B | $974.0M | $1.14B |
| 総負債 | $586.0M | $551.0M | $687.0M | $665.0M | $625.0M | $526.0M | $538.0M | $508.0M |
| 株主資本 | $707.0M | $635.0M | $565.0M | $485.0M | $531.0M | $549.0M | $436.0M | $631.0M |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $-2.0M | $-94.0M | $26.0M | $-100.0M | $-132.0M | $-133.0M | $-97.0M | $-120.0M |